Fennec Pharmaceuticals, a US-based pharmaceutical company, specializes in developing products focused on ESG principles. With an ESG score of 28.1, the company is categorized as a medium-risk investment. Their main product, PEDMARK, is designed to prevent cisplatin-induced hearing loss in children. Fennec Pharmaceuticals is dedicated to promoting sustainability and governance in the healthcare industry.